Epigenomics and DxS Enter Into Strategic Cross-Licensing Agreement for the Use of Scorpions Technology in DNA Methylation:

Current News

Contact | Print version | PDF version | Send article | RSS-Feed

Epigenomics and DxS Enter Into Strategic Cross-Licensing Agreement for the Use of Scorpions Technology in DNA Methylation

15 Jan 2008 - Epigenomics AG (and DxS Ltd. announced that they have entered into a strategic cross-licensing agreement. Under the terms of the agreement, Epigenomics obtains worldwide non-exclusive rights to DxS' proprietary Scorpions� technology for R&D use and research kits, as well as an option to expand the license to the in vitro diagnostics (IVD) field. Epigenomics intends to use this technology both in certain research kits as well as potentially in its cancer specialty diagnostics products. DxS in return receives an option for a worldwide non-exclusive license and further options to certain Epigenomics IP covering the use of Scorpions� technology for DNA methylation applications. Both Epigenomics and DxS have acquired options to sub-licensing rights for the respective technologies.

�
Further details and financial terms of the agreement were not disclosed.

�

Additional information